Menu

Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


09. September 2020 | 06:26 CET

Naga Group, Triumph Gold, UmweltBank - who has a crisis-resistant business model?

  • Covid-19

In times of the Corona Pandemic, many companies have learned the limits of their resilience. There are winners and losers as well as market participants who have not experienced any changes. When the panic in the markets was at its peak in March 2020, the price of gold was also on a downward trend. A few months later, the symbolic USD 2,000.00 mark was already exceeded. The measures taken by the central banks are leading to different developments in the various sectors of economic life and investors can benefit from this.

time to read: 3 minutes by Mario Hose


 

TRIUMPH GOLD CORP - Golden times in the Yukon

In July 2020, the Canadian exploration company Triumph Gold announced plans for the upcoming exploration season at its 200 km2 Freegold Mountain project. The area is located in the Dawson Range region of the mining-friendly Yukon and a significant advantage is that it is accessible by road. The project hosts three NI 43-101 compliant mineral deposits and covers a significant portion of the Big Creek Fault Zone - a structure associated with epithermal gold and silver mineralization and gold-rich porphyry copper mineralization.

"The 2020 exploration program is aimed at unlocking the higher-grade gold areas of the Freegold Mountain project that our technical team have been working on over the past couple of years," said John Anderson, executive chairman. "Now that there is a clear path to be able to work in Yukon given delays due to COVID-19, we are very pleased to start drilling the first week of August. We are truly excited about what these projects can deliver using a 'gold-first' exploration focus.".

The results of this drill program are eagerly awaited. Newmont is Triumph Gold's largest shareholder and at current gold price levels, an acquisition by a producer may be a possible scenario as reserves increase. The market value of the company is currently around CAD 40 million and would be easily shouldered by the major producers even at a significant premium. Access to the oldest currency in the world can't hurt.

UMWELTBANK AG - the bank that does good

UmweltBank AG stands for banking transactions with ecological and social responsibility. It offers investors transparent ecological investments and supports private individuals and commercial customers throughout Germany by financing environmentally friendly projects. According to GBC Research, UmweltBank is consistently implementing its ecological orientation by exclusively offering a green product range.

In addition to the classic savings account, the company offers green fund products, makes ecological investments, offers ecological insurance policies and finances green projects, among other things. In doing so, UmweltBank functions as a direct bank, without the classic branch business. Since its foundation in 1997, more than 23,500 loan projects have been supported. At the end of 2019, environmental loans with a total volume of EUR 2.6 billion were on the books. The majority of the loan volume consists of solar energy financing, residential real estate and wind and hydroelectric power projects.

Even during the Covid 19 pandemic, the business model of UmweltBank AG proved to be comparatively sound, as expected. For the most part, GBC analysts have left their previous forecasts unchanged and have only included earnings forecasts for the current 2020 financial year.Although they expect all earnings components to improve in the second half of 2020, overall they are likely to be slightly below their expectations. The analysts therefore reduce their net interest income forecast from EUR 51.66 million to EUR 50.43 million. However, they still confirm their price target of EUR 14.50 and maintain their "BUY" rating.

NAGA GROUP AG - impressive restructuring

The Naga Group is an innovative Fintech company that seamlessly connects personal financial transactions and investments with its social media trading platform. The platform offers a variety of products ranging from stock trading, investments and crypto-currencies to a physical Mastercard. In addition, the platform enables exchange with other merchants, provides relevant information in the feed and autocopy functions for the trades of successful members.

Against the background of the initiated restructuring and taking into account the high capital market volatility in the environment of the Covid 19 pandemic, the Naga Group has achieved high growth rates in the first months of 2020, according to analysts from GBC Research. In the first half of 2020, the Naga Group achieved sales revenues of about EUR 12.1 million (previous year: EUR 1.7 million) with an EBITDA margin of about 30.5 %, corresponding to an EBITDA of about EUR 3.7 million (previous year: EUR -4.6 million).

This development is based on the number of new customers of more than 46,000 users (previous year: 18,500) and the significant increase in the trading volume to around EUR 50 billion (previous year: EUR 16.5 billion). The successful development continued in July, when a turnover of around EUR 2.2 million was achieved with a trading volume of almost EUR 10 billion. As part of their DCF valuation model, GBC's analysts have set a target price of EUR 3.75 per share and continue to assign a "BUY" rating.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

23. September 2020 | 09:05 CET

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

  • Covid-19

When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.

Read

18. September 2020 | 06:00 CET

BioNTech, CureVac, EXMceuticals - reaching their goal with government support

  • Covid-19

In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and active ingredients are being sought to combat Covid-19. Above all, the common good of all is the primary focus of political institutions and for this reason they are not letting research-based companies down and are attracting them with special permits and subsidies. Ultimately, everyone around the world will likely benefit from this.

Read

11. September 2020 | 09:59 CET

BioNTech, CureVac, Valeo Pharma - Growth after capital injection

  • Covid-19

Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to the market with a product first is de facto guaranteed high sales and profits. However, there is not much time left for the development of a vaccine against Covid-19 and to reduce the economic damage, researching companies have virtually unlimited amounts of money available. Whoever finds a solution against Covid-19 will certainly have the right team in the starting blocks in the fight against the subsequent Corona viruses.

Read